http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
류마티스 관절염 환자에서 발생한 Mycobacterium intracellulare에 의한 관절염 1예
박근우,권현희,정승혜,김경찬,최정윤,이영환 대한감염학회 2007 감염과 화학요법 Vol.39 No.1
비정형 항산균에 의한 근골격계 감염은 매우 드물며, 진단이 지연되는 경우가 많다. 저자들은 류마티스 관절염환자에서 수차례 스테로이드 주사 후에 생긴 M. intracellulare에 의한 관절염을 진단하고 수술적 치료없이 약물 치료만으로 좋은 결과를 보인 예를 경험하였기에 보고하는 바이다. Nontuberculous mycobacteria are ubiquitous organisms that are frequently present in the water, soil and animal reservoirs. Nontuberculous mycobacterial infections of the musculoskeletal system are rare and usually associated with predisposing factors, such as prior joint disease, trauma, use of intraarticular or oral corticosteroids, or an immunocompromised state. A sixty five-year-old patient with rheumatoid arthritis was hospitalized due to swelling on the left wrist. M. intracellulare was cultured from the aspirated joint fluid. The patient was successfully treated with clarithromycin, ethambutol, and rifampin. We report this case with review, emphasizing high suspicion for nontuberculous mycobacterial infection in patients with predisposing risk factors.
정승혜 ( Seung Hie Chung ),이진배 ( Jin Bae Lee ),임상혁 ( Sang Hyuk Lim ),김채기 ( Chae Gi Kim ),최정윤 ( Jung Yoon Choe ) 대한류마티스학회 2002 대한류마티스학회지 Vol.9 No.4
Overlap syndrome is used to describe patients who have two or more well-defined connective tissue diseases. Although a variety of overlap syndromes are now recognized, the coexistence of the progression of juvenile rheumatoid arthritis (JRA) to systemic lupus erythematosus (SLE) is uncommon. We describe a patient who had typical deforming polyarthritis, who years later developed SLE.
저세포성 골수를 보인 환자에서 저용량 Ara-C 치료 후 급성골수성백혈병으로 진단된 1예
정승혜,박성훈,정성창,진명인,박민식,류헌모,김상경,조창호,이재련 대한조혈모세포이식학회 2002 대한조혈모세포이식학회지 Vol.7 No.1
저세포성 급성골수성백혈병은 골수 검사 결과 세포충실도가 5~40%이면서 백혈구 아세포가 30% 이상이 되는 경우를 말하며 급성백혈병 중 5~10%를 차지한다. 저세포성 급성골수성백혈병에서 low-dose Ara-C는 골수양 분화를 항진시킴으로 치료 효과를 가진다고 알려져 있다. 저자들은 저세포성 급성골수성백혈병 또는 저세포성 골수이형성증후군이 의심되어 low-dose Ara-C를 투여한 후 세포충실도의 증가를 보이며, 후에 급성골수성백혈병으로 진행하는 증례를 경험하였다. 본 증례에서는 low-dose Ara-C 투여 후 골수의 세포충실도의 증가를 확인할 수 있어 low-dose Ara-C의 분화 유도 효과를 뒷받침해 준다고 볼 수 있다. 환자는 idarubicin과 Ara-C 병용 요법으로 관해유도요법을 시행한 후 완전관해에 도달하여 공고요법 중이다. Hypocellular AML occurs in 5 to 10% of patients with AML, and has been described as a subset of AML with a cellularity between 5 and 40% when the blast % exceeds 30% of all the nucleated bone marrow (BM) cells. Low-dose cytosine arabinoside (Ara-C) in patients with hypocellular AML is known to be an effective regimen with some clinical benefits through the action of myeloid differentiation. We experienced a 56- year-old female with pancytopenia in the peripheral blood and a hypocellular marrow. She was diagnosed of having either hypocellular AML or hypocellular MDS and chemotherapy with low- dose Ara-C was started. Her BM cellularity increased to 10%. Two months later she was admitted again with thrombocytopenia with a BM cellularity of 75% and was diagnosed of AML (FAB M2). The increase in BM cellularity supported the myeloid differentiation effect of low-dose Ara-C. She achieved complete remission after receiving a combination regimen of idarubicin and Ara-C and is presently undergoing postremission therapy.
건강 검진자에서의 Helicobacter pylori 혈청학적 유병률
임정윤 ( Jeong Yoon Yim ),최승호 ( Seung Ho Choi ),박민정 ( Min Jeong Park ),김영선 ( Young Sun Kim ),임선희 ( Sun Hie Lim ),조경란 ( Keong Ran Choi ),김동희 ( Dong Hie Kim ),김충현 ( Chung Hyun Kim ),정인경 ( In Keong Jung ),최 대한내과학회 2006 대한내과학회지 Vol.70 No.6
Background: H. pylori-associated gastrointestinal diseases have been widely recognized. The aim of this study was to investigate the seropositivity of H. pylori in health check-up subjects and to find out the relating factors. Methods: From November 2004 through June 2005, total 7,676 health check-up subjects (age≥20) responded to the self administered questionnaires. The prevalence of H. pylori was assessed by measuring anti-H. pylori IgG antibodies. Results: The overall seropositivity was 56.7% in 7,676 and 1,137 (14.8%) has been found to have history of H. pylori eradication therapy. The seropositivity rate of H. pylori was 61.3% (2,653) in 4,328 subjects without history of H. pylori eradication and current gastrointestinal symptoms. Seroprevalence of H. pylori was significantly lower in 20~29 years old, female, high income and subjects from Seoul respectively. Conclusions: The seropositivity of H. pylori in 2004~2005 is found to be 61.3% in subjects without history of H. pylori eradication and current gastrointestinal symptoms. This seems to be lower than 66.9%, the seroprevalence rate in asymptomatic Korean population in the age of ≥16 years in 1998. This decrease might be caused by improvement of socioeconomic status.(Korean J Med 70:636-642, 2006)